GluSense, which is developing a long-term glucose-monitoring implant, has received approximately $1.9 million from the newly launched JDRF T1D Fund.

Disposable diabetes device maker Valeritas has filed to raise $50 million by listing its stock on Nasdaq.

Ivantis reeled in a $25 million Series C round to advance the development of its glaucoma-treating microstent through commercialization.

Illumina cancer-screening spinoff Grail declared Thursday that it intends to raise more than $1 billion in its Series B round. A $1 billion round—pretty much…

Cerêve bagged a $38 million Series B that will help propel the commercial launch of its insomnia-treating device in the latter half of this year.

Braeburn Pharmaceuticals has filed for a $150 million IPO to fund commercialization of its six-month opioid addiction implant.

Intarcia has raised $206 million in a second close of its Series EE financing, with the Bill & Melinda Gates Foundation pitching in a $50 million…

Providence Medical Technology reeled in $10.5 million to build up and commercialize its portfolio of cervical-fusion devices used in spinal surgery.